Context Therapeutics up after drug shows promise in breast cancer study

Context Therapeutics

10/12/2021 11:09

** Shares of drug developer  CNTX.O  rise 24.9% to $7.82
premarket
    ** Co says its experimental drug, ONA-XR, significantly
increased the suppression of tumor cells in a
window-of-opportunity trial in patients with a type of breast
cancer  urn:newsml:reuters.com:*:nGNX2d16hG
    ** Window of opportunity studies are trials in which
patients receive one or more new compounds between their cancer
diagnosis and standard treatment
    ** The study, conducted by Spanish cancer research group
SOLTI, enrolled 10 patients
    ** Tumor expression decreased in six patients, remained
stable in one patient, and increased in three patients - CNTX
    ** ONA-XR is being evaluated in four trials in
hormone-driven breast, ovarian and endometrial cancers
    ** Stock has gained 22.7% since October IPO

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))